- Stocks
- Healthcare
- NASDAQ: ALBO

Price (delayed)

$31.95

Market cap

$615.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.34

Enterprise value

$438.79M

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and

The equity has increased by 27% year-on-year but it has declined by 23% since the previous quarter

The gross profit has contracted by 18% YoY but it has grown by 6% from the previous quarter

The net income has dropped by 66% year-on-year and by 13% since the previous quarter

The quick ratio is down by 29% since the previous quarter and by 22% year-on-year

What are the main financial stats of ALBO

Market
Valuations
Earnings

Shares outstanding

19.26M

Market cap

$615.22M

Enterprise value

$438.79M

Price to earnings (P/E)

N/A

Price to book (P/B)

5.4

Price to sales (P/S)

66.39

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

47.48

Revenue

$9.24M

EBIT

-$121.32M

EBITDA

-$121.13M

Free cash flow

-$120.35M

Per share
Balance sheet
Liquidity

EPS

-$7.34

Free cash flow per share

-$6.27

Book value per share

$5.91

Revenue per share

$0.48

TBVPS

$10.53

Total assets

$219.5M

Total liabilities

$105.99M

Debt

$9.86M

Equity

$113.5M

Working capital

$168.26M

Debt to equity

0.09

Current ratio

7.23

Quick ratio

6.9

Net debt/EBITDA

1.46

Margins
Efficiency
Dividend

EBITDA margin

-1,310.7%

Gross margin

100%

Net margin

-1,468.4%

Operating margin

-1,312.8%

Return on assets

-50.9%

Return on equity

-82.9%

Return on invested capital

-7,283%

Return on capital employed

-63%

Return on sales

-1,312.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Albireo Pharma stock price performed over time

Intraday

0%

1 week

1.14%

1 month

7.14%

1 year

-2.89%

YTD

-14.82%

QTD

-9.18%

How have Albireo Pharma's revenue and profit performed over time

Revenue

$9.24M

Gross profit

$9.24M

Operating income

-$121.32M

Net income

-$135.7M

Gross margin

100%

Net margin

-1,468.4%

The net margin has dropped by 103% year-on-year and by 7% since the previous quarter

ALBO's operating margin has dropped by 89% year-on-year and by 8% since the previous quarter

The net income has dropped by 66% year-on-year and by 13% since the previous quarter

The company's operating income has shrunk by 55% YoY and by 14% QoQ

What is Albireo Pharma's growth rate over time

What is Albireo Pharma stock price valuation

P/E

N/A

P/B

5.4

P/S

66.39

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

47.48

Albireo Pharma's EPS has decreased by 24% YoY and by 8% QoQ

ALBO's price to book (P/B) is 69% higher than its 5-year quarterly average of 3.2 and 29% higher than its last 4 quarters average of 4.2

The equity has increased by 27% year-on-year but it has declined by 23% since the previous quarter

The price to sales (P/S) is 99% lower than the 5-year quarterly average of 10058.6

The revenue has contracted by 18% YoY but it has grown by 6% from the previous quarter

How efficient is Albireo Pharma business performance

Albireo Pharma's return on invested capital has shrunk by 152% QoQ but it has increased by 42% YoY

Albireo Pharma's return on sales has shrunk by 99% YoY and by 8% QoQ

Albireo Pharma's return on assets has decreased by 10% YoY and by 9% QoQ

Albireo Pharma's return on equity has decreased by 9% QoQ

What is ALBO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ALBO.

How did Albireo Pharma financials performed over time

The total assets is 107% more than the total liabilities

Albireo Pharma's current ratio has decreased by 29% from the previous quarter and by 22% YoY

The quick ratio is down by 29% since the previous quarter and by 22% year-on-year

The debt is 91% smaller than the equity

The debt to equity has grown by 29% since the previous quarter but it has declined by 18% year-on-year

The equity has increased by 27% year-on-year but it has declined by 23% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.